It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cancer is the second leading cause of death and there is an urgent need to improve cancer management. We have developed an innovative cancer therapy named Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) by combining gold nanostars (GNS)-mediated photothermal ablation with checkpoint inhibitor immunotherapy. Our previous studies have demonstrated that SYMPHONY photoimmunotherapy not only treats the primary tumor but also dramatically amplifies anticancer immune responses in synergy with checkpoint blockade immunotherapy to treat remote and unresectable cancer metastasis. The SYMPHONY treatment also induces a ‘cancer vaccine’ effect leading to immunologic memory and prevents cancer recurrence in murine animal models. This manuscript provides an overview of our research activities on the SYMPHONY therapy with plasmonic GNS for cancer treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA; Department of Chemistry, Duke University, Durham, NC, 27708, USA; Fitzpatrick Institute of Photonics, Duke University, Durham, NC, 27708, USA
2 Department of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA
3 Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA; Fitzpatrick Institute of Photonics, Duke University, Durham, NC, 27708, USA
4 Division of Urology, Duke University Medical Center, Durham, NC, 27710, USA
5 Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA; Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA; Department of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
6 Fitzpatrick Institute of Photonics, Duke University, Durham, NC, 27708, USA; Department of Electrical and Computer Engineering, Duke University, Durham, NC, 27708, USA
7 Fitzpatrick Institute of Photonics, Duke University, Durham, NC, 27708, USA; Department of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA
8 Fitzpatrick Institute of Photonics, Duke University, Durham, NC, 27708, USA; Division of Urology, Duke University Medical Center, Durham, NC, 27710, USA